Skip to main content
. 2020 Dec 14;11:606923. doi: 10.3389/fneur.2020.606923

Figure 3.

Figure 3

Evolution of CD19+ B-cell counts during the follow-up periods. For most (75%) patients treated with rituximab, CD19+ B-cell depletion occurred rapidly within 1 week after the first infusion of rituximab.